Recursion Pharmaceuticals, Inc. RXRX Finance Lease Liabilities
Finance Lease Liabilities at other companies
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:FinanceLeaseLiability.
The official record: Recursion Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Recursion Pharmaceuticals, Inc.'s finance lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Recursion Pharmaceuticals, Inc.'s finance lease liabilities?
- Recursion Pharmaceuticals, Inc. (RXRX) reported finance lease liabilities of $16.2M in Q1 2026.
- How has Recursion Pharmaceuticals, Inc.'s finance lease liabilities changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s finance lease liabilities decreased by 34.1% year-over-year, from $24.6M to $16.2M.
- What does finance lease liabilities mean?
- Present value of future payments on leases classified as finance leases under ASC 842 — treated similarly to debt on the balance sheet.